This Article Full Text Full Text (PDF) An erratum has been published Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bressler, L. R. Articles by Schilsky, R. L. Search for Related Content PubMed Articles by Bressler, L. R. Articles by Schilsky, R. L.

Collaboration Between Cooperative Groups and Industry

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Linda R. Bressler, PharmD

The proper relationship between academic investigators and the pharmaceutical industry when conducting large, multicenter, prospective, randomized clinical trials is controversial and can be tense. The potentially conflicting goals of government-funded cooperative groups and pharmaceutical industry sponsors was the subject of a recent commentary in Nature¹ by Martine Piccart, current President of the European Organisation for Research and Treatment of Cancer and her colleagues. They expressed particular concern that important features of clinical trials—the design, the duration of patient follow-up, the conduct of any subset analysis, and the adverse event analysis and reporting—may be excessively influenced or . . . [Click for More]